Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: Retrospective analysis of survival after long-term follow-up

Abstract We designed a protocol (VAPA) that featured 14 mo of intensive postremission induction chemotherapy in an effort to improve remission durations for patients with acute myelogenous leukemia (AML). One hundred and seven patients under 50 yr of age were entered into this study. The rate of complete remission is 70%. A Kaplan-Meier analysis of patients entering remission predicts that 56% +/- 7% (+/-SE) of patients less than 18 yr and 45% +/- 9% of patients aged 18–50 yr will remain in remission at 3 yr (median follow-up is 43 mo). Patients with the monocytic subtype had a statistically significant shorter duration of remission (2-sided p less than 0.05). There was a high incidence of primary CNS relapse in children. Thirty-one of 41 patients who completed the regimen remain in remission without maintenance therapy. We conclude that the VAPA protocol continues to offer a promising approach to treatment of AML.

Download Full-text

Abstract 3311: The alteration in key regulator genes of autophagy is mainstream mechanism of therapy resistance and impact prognosis of acute myelogenous leukemia (AML): results from diagnosis genomic analysis on 148 consecutive patients treated with intensive chemotherapy and long-term survival follow-up

10.1158/1538-7445.am2017-3311 ◽

2017 ◽

Author(s):

Giovanni Marconi ◽

Cristina Papayannidis ◽

Maria Chiara Fontana ◽

Antonella Padella ◽

Anna Ferrari ◽

...

Keyword(s):

Acute Myelogenous Leukemia ◽

Genomic Analysis ◽

Therapy Resistance ◽

Myelogenous Leukemia ◽

Intensive Chemotherapy ◽

Term Survival ◽

Acute Myelogenous ◽

Regulator Genes

Download Full-text

Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update

Blood ◽

10.1182/blood.v62.2.315.bloodjournal622315 ◽

1983 ◽

Vol 62 (2) ◽

pp. 315-319 ◽

Cited By ~ 1

Author(s):

HJ Weinstein ◽

RJ Mayer ◽

DS Rosenthal ◽

FS Coral ◽

BM Camitta ◽

...

Keyword(s):

Complete Remission ◽

Maintenance Therapy ◽

Induction Chemotherapy ◽

Acute Myelogenous Leukemia ◽

Myelogenous Leukemia ◽

Kaplan Meier ◽

High Incidence ◽

Acute Myelogenous ◽

Leukemia In Children

We designed a protocol (VAPA) that featured 14 mo of intensive postremission induction chemotherapy in an effort to improve remission durations for patients with acute myelogenous leukemia (AML). One hundred and seven patients under 50 yr of age were entered into this study. The rate of complete remission is 70%. A Kaplan-Meier analysis of patients entering remission predicts that 56% +/- 7% (+/-SE) of patients less than 18 yr and 45% +/- 9% of patients aged 18–50 yr will remain in remission at 3 yr (median follow-up is 43 mo). Patients with the monocytic subtype had a statistically significant shorter duration of remission (2-sided p less than 0.05). There was a high incidence of primary CNS relapse in children. Thirty-one of 41 patients who completed the regimen remain in remission without maintenance therapy. We conclude that the VAPA protocol continues to offer a promising approach to treatment of AML.

Download Full-text